Abstract | BACKGROUND: METHODS: This was a retrospective collaborative cohort study combining two prospectively collected UK institutional databases of patients with oesophageal adenocarcinoma. Multivariable Cox regression and propensity matched analyses were used to compare overall and recurrence-free survival according to the adjuvant treatment. RESULTS: Of 374 patients with clear resection margins, 221 patients (59%) had no adjuvant treatment, 137 patients (37%) had adjuvant chemotherapy and 16 patients (4%) had adjuvant chemoradiotherapy. For patients who had received NAC (290, 76%), when adjuvant chemotherapy was compared to no adjuvant treatment, hazard ratios (HRs) favoured adjuvant chemotherapy but did not reach independent significance (overall survival [OS] HR 0.65 95% confidence interval [CI] 0.40-1.06; p .0.087). Responders to NAC (Mandard 1-3) were seemingly more likely to demonstrate a survival benefit from adjuvant chemotherapy (HR 0.42 95% CI 0.15-1.11; p .1.081). CONCLUSIONS: Although no independent survival benefit was observed, the point estimates favoured adjuvant treatment, predominantly in patients with chemo-responsive tumours.
|
Authors | Rebecca K Bott, Kerri Beckmann, Janine Zylstra, Michelle J Wilkinson, William R C Knight, Cara R Baker, Mark Kelly, Nick Maisey, Justin Waters, Mieke Van Hemelrijck, Elizabeth C Smyth, William H Allum, Jesper Lagergren, James A Gossage, David Cunningham, Andrew R Davies |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 60
Issue 5
Pg. 672-680
(May 2021)
ISSN: 1651-226X [Electronic] England |
PMID | 33586602
(Publication Type: Journal Article)
|
Topics |
- Adenocarcinoma
(drug therapy)
- Chemoradiotherapy, Adjuvant
- Chemotherapy, Adjuvant
- Cohort Studies
- Humans
- Margins of Excision
- Neoadjuvant Therapy
- Retrospective Studies
|